A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma
Status:
Terminated
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the combination of everolimus and imatinib will
slow the growth of or cause a reduction in the size of the cancer, and to determine the side
effects of the combination in patients with melanoma. Each of the drugs in this combination,
if used alone, would not be expected to have an effect against the cancer. However, when used
together, there is a possibility that they could work together to damage the cancer cells, or
to block the formation or function of the blood vessels that feed the cancer, either of which
could result in slowing the growth of or shrinking the cancer. Both drugs work by blocking
signals that are sent from outside of a cell to the inside of the cell that direct the cell
to make certain substances to keep the cell alive. Cancer cells or blood vessels that feed
cancer cells may be more sensitive to drugs that block these signals.